BLFS — BioLife Solutions Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.16bn
- $1.16bn
- $143.27m
- 69
- 22
- 95
- 64
2019 December 31st | C2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.66 | 1.98 | -8.91 | -140 | -66.4 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 7.09 | 3.99 | 13.8 | 135 | 40.2 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.47 | -1.1 | -2.26 | -14.9 | 1.47 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 1.21 | 6.64 | -4.59 | -8.49 | -12.5 |
Capital Expenditures | -2.33 | -7.81 | -14.8 | -13.9 | -11.2 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -24.7 | -16.9 | 1.56 | -44.2 | 29.1 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -27 | -24.7 | -13.2 | -58.1 | 17.8 |
Financing Cash Flow Items | 0.415 | -0.499 | -1.3 | -1.84 | 0.338 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.6 | 102 | -2.78 | 16.3 | 10.6 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -24.2 | 84 | -20.6 | -50.4 | 16 |